Fig. 1 · Structure

Documents & Downloads

Scutellarein

Cat. No. A12234 CAS 529-53-3
Scutellarin, a main active ingredient extracted from Erigeron breviscapus (Vant.) Hand-Mazz, has been wildly used to treat acute cerebral infarction and paralysis induced by cerebrovascular diseases.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
HEK293 EC50 16.4 μM Agonist activity at mouse PPARgamma expressed in HEK293 cells co-expressing with Gal4 reporter vector after 24 hrs by dual-luciferase reporter assay [PMID: 24955889]
MV4-11 IC50 27.07 μM Antiproliferation activity against human MV4-11 cells assessed as reduction in cell viability measured by Cell-titer-Glo assay [PMID: 32088124]
RBL-2H3 IC50 67.2 μM Antihistaminic activity in rat RBL2H3 cells assessed as inhibition of DNP-BSA-induced beta-hexosaminidase release preincubated for 10 mins before DNP-BSA challenge [PMID: 14510616]

Scutellarein Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Scutellarein from 3 published references. In vitro models include PC12 cells; AGS.

Scutellarein In Vitro Studies

In PC12 cells coincubated with H2O2, Scutellarein produced reported inhibiting rates of 94.92%, 35.32% and 4.57% at 100 μmol/L, 10 μmol/L and 1 μmol/L, respectively, relative to the H2O2 group. In AGS cells, Scutellarein had cell viability IC50 values of 62.88 μM at 24 h and 49.18 μM at 48 h. In HT1080 human fibrosarcoma cells, Scutellarein at 10 and 50 μm/l reduced cell viability by 27.6% and 32.8%, respectively, compared with DMSO-treated cells. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Inhibiting rates in peroxide-exposed cells

Cell-based study · PC12 cells [1]

PC12 cells were coincubated with Scutellarein and H2O2 for 3 h. At Scutellarein concentrations of 100 μmol/L, 10 μmol/L and 1 μmol/L, reported inhibiting rates were 94.92%, 35.32% and 4.57%, respectively, relative to the H2O2 group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibiting Rate (%)H2O2-induced cytotoxicity 94.92%; 35.32%; 4.57%[1]

Literature-Reported Treatment Conditions

Treatment concentration
100 μmol/L; 10 μmol/L; 1 μmol/L
Exposure duration
3 h with H2O2
Method
coincubation of PC12 cells with sample and H2O2
Co-treatment
Other interventions in this design: H2O2 400 μmol/L. Compound effect isolated by the comparison: A1 was the absorbance in the presence of sample and H2O2, A2 was the absorbance in the presence of H2O2 (model).
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Scutellarein

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.6. MTT Assay for PC12 Cell Survival (S31, S34, S35, S37); Table 3 legend (S42); Table 3 (T3.h1, T3.h2, T3.r4, T3.r5, T3.r6)

Inhibiting Rate (%): Inhibiting Rate (%); comparator: H2O2 group — Table 3 (T3.h1, T3.h2, T3.r4, T3.r5, T3.r6)

Cell viability in AGS cells

Cell-based study · AGS [2]

AGS cells were treated with Scutellarein, with DMSO alone as the vehicle control. Cell viability IC50 values were 62.88 μM at 24 h and 49.18 μM at 48 h.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell viabilityIC50 62.88 μM at 24 h and 49.18 μM at 48 h[2]

Literature-Reported Treatment Conditions

Treatment concentration
25, 50, 75 and 100 μM
Exposure duration
24 and 48 h
Vehicle
DMSO
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Scutellarein

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > Scutellarein inhibited cell proliferation in AGS and SNU-484 gastric cancer cells (S1, S6); MATERIALS AND METHODS > Cell viability assay (S70, S71); Figure 1 legend (S117)

Cell viability: Cell viability; comparator: vehicle (DMSO) alone — RESULTS > Scutellarein inhibited cell proliferation in AGS and SNU-484 gastric cancer cells (S6); Figure 1 legend (S117)

Cell viability in human fibrosarcoma cells

Cell-based study · HT1080 human fibrosarcoma cells [3]

HT1080 human fibrosarcoma cells were treated with Scutellarein for 24 h. Concentrations of 10 and 50 μm/l reduced cell viability by 27.6% and 32.8%, respectively, compared with DMSO-treated cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MTT assay (n=5)cell viability 27.6% and 32.8% reduction in cell viability[3]

Literature-Reported Treatment Conditions

Treatment concentration
10 and 50 μm/l
Exposure duration
24 h
Method
fresh medium containing 2 different concentrations (10 and 50 μm/l) of scutellarein
Vehicle
10% dimethyl sulfoxide (DMSO)
Methods and source locations

Compound reported in the paper: Scutellarein

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Drugs (S2); Materials and methods > Cell viability (MTT) assay (S13, S16); Results > Anti-proliferative effects of scutellarein against HT1080 fibrosarcoma cells (S86); Figure 1 legend (S131)

MTT assay (n=5): MTT assay (n=5); comparator: DMSO-treated cells — Results > Anti-proliferative effects of scutellarein against HT1080 fibrosarcoma cells (S86); Figure 1 legend (S131)

Scutellarein In Vivo Studies

Scutellarein was administered by intraperitoneal injection to male Balb/c nude mice bearing HT1080-induced fibrosarcomas after tumors had grown. Doses of 0.05 and 0.5 μg/g suppressed tumor weight by 30.25% and 46.17%, respectively, compared with the PBS-treated control group. [3]

Tumor weight in a mouse fibrosarcoma model

Animal study · Male Balb/c nude mice (5 weeks old); Fibrosarcoma formation was induced by injecting HT1080 cells into Balb/c nude mice; n=6 [3]

Male Balb/c nude mice bearing HT1080-induced fibrosarcomas received Scutellarein by intraperitoneal injection after tumors had grown. Doses of 0.05 and 0.5 μg/g suppressed tumor weight by 30.25% and 46.17%, respectively, compared with the PBS-treated control group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
tumor weighttumor weight suppressed the tumor weight by 30.25% and 46.17%[3]

Conditions shared by the study groups

Route
intraperitoneal injection
Treatment course
After the tumors had grown; At 20 days following the injection of the cancer cells
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Scutellarein 0.05 and 0.5 μg/gcontrol group treated with PBSThe injection of scutellarein at doses of 0.05 and 0.5 μg/g, suppressed the tumor weight by 30.25% and 46.17%, respectively, in comparison to the control group treated with PBS[3]
Scutellarein 0.05 and 0.5 μg/g
Model: Male Balb/c nude mice (5 weeks old); Fibrosarcoma formation was induced by injecting HT1080 cells into Balb/c nude mice; n=6
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Scutellarein

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Animal experiments (S76, S77, S78, S80); Results > Scutellarein attenuates fibrosarcoma in vivo (S95, S96, S97); Figure 3 legend (S143)

tumor weight: tumor weight; comparator: control group treated with PBS — Materials and methods > Animal experiments (S80); Results > Scutellarein attenuates fibrosarcoma in vivo (S97)

Scutellarein 0.05 and 0.5 μg/g · Materials and methods > Animal experiments (S78); Results > Scutellarein attenuates fibrosarcoma in vivo (S96, S97)

Specifications

Manufacturer Adooq Bioscience
CAS Number 529-53-3
Formula C15H10O6
Molecular Weight 286.24
Synonyms 6-Hydroxyapigenin
SMILES
C1=CC(=CC=C1C2=CC(=O)C3=C(C(=C(C=C3O2)O)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 50 mg/mL (174.68 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Scutellarein Research References

  1. [1] Qian LH, Li NG, Tang YP, et al. Synthesis and bio-activity evaluation of scutellarein as a potent agent for the therapy of ischemic cerebrovascular disease. Int J Mol Sci (2011). PMID: 22174659 DOI: 10.3390/ijms12118208 Source material
  2. [2] Gowda Saralamma VV, Lee HJ, Raha S, et al. Inhibition of IAP's and activation of p53 leads to caspase-dependent apoptosis in gastric cancer cells treated with Scutellarein. Oncotarget (2018). PMID: 29464049 DOI: 10.18632/oncotarget.23202 Source material
  3. [3] Shi X, Chen G, Liu X, et al. Scutellarein inhibits cancer cell metastasis in vitro and attenuates the development of fibrosarcoma in vivo. Int J Mol Med (2015). PMID: 25394920 DOI: 10.3892/ijmm.2014.1997 Source material

Added to your cart

View Cart Checkout
Loading...